GSD SARS-CoV-2 IgG (1x96)
The SARS-CoV-2 (COVID-19) IgG ELISA is intended for the qualitative determination of IgG class antibodies against SARS-CoV-2 in human serum or plasma (citrate, heparin) to support the diagnosis of COVID-19 disease and constitutes a supplement to direct pathogen detection. In addition, serology can be used to collect epidemiological information on the prevalence of SARS-CoV-2.
SARS-CoV-2 IgG, IgA and IgM ELISAs are intended for the qualitative detection of IgG, IgA and IgM antibodies to SARS-CoV-2 virus in human serum to aid in the diagnosis of Coronavirus (COVID-19). The assays are an ideal supplement for direct pathogen detection and are a valuable tool for epidemiological studies.
The qualitative immunoenzymatic determination of specific antibodies is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique. Microtiter plates are coated with specific antigens to bind corresponding antibodies of the sample. After washing the wells to remove all unbound sample material a horseradish peroxidase (HRP) labeled conjugate is added. This conjugate binds to the captured antibodies. In a second washing step, unbound conjugate is removed. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of specific antibodies in the sample. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450/620 nm is read using an ELISA Microtiter plate reader.
|Test principle||Enzyme-linked Immunosorbent Assay|
|Format||Microtiter plate with 96 wells|
|Incubation Time||2 hours|
|Shelf Life (months)||6|